• Antibody-drug conjugates
• Targeting platform – 'OptiLink'
• Light activated cancer therapy – 'ProstaLite'
• MRI contrast agents & imaging
• Photosensitiser innovations
• Additional products and applications

• Investment History & Strategy
• Partnering opportunities

• Press Releases
• News Items
• Scientific Publications

• Background
• Achievements
• The Team
• Sitemap

Innovative Targeted Therapeutics from PhotoBiotics

About Us

PhotoBiotics Ltd is a multidisciplinary spin-out from Imperial College London UK which combines chemistry, photophysics, and biochemistry ... read more »

Technology / Pipeline

Antibody fragment with PhotoBiotics' Optilink proprietary conjugation technology being used to attach a variety of agents, in this case for phototherapy and MRI diagnosis

Antibody-drug conjugates are expected to be the next generation of antibody therapeutics. Current unmodified monoclonal antibodies (MAbs) do not cure, and can only extend survival by 5-6 months. In addition, many antibodies suffer from drug resistance due to mutations in cell-signalling pathways.

OptiLink™ is a unique and simple conjugation platform for better drug delivery in imaging and therapy. It enables multiple loading of drug molecules and imaging agents onto specifically bio-engineered antibody fragments... read more »

OptiLink™ technology is currently being used with photosensitiser innovations to create ProstaLite, a promising novel targeted light activated therapy for prostate cancer.

As our pipeline evolves, OptiLink™ will deliver novel targeted 'see and treat' agents to improve efficacy and tolerability of treatment, significantly shorten tumour treatment times, and improve quality of life for patients... read more »